A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2018
At a glance
- Drugs SEA-BCMA (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 14 Nov 2018 According to a Seattle Genetics, Inc. media release, first patient has been dosed in this trial.
- 20 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.